title: Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study.
abstract: OBJECTIVE
  The aim of the study was to investigate the 5-yr impact of surgery and somatostatin analogs (SSA) on glucose metabolism in acromegaly.
  
  
  METHODS
  We conducted an observational, prospective, comparative, nonrandomized study.
  
  
  METHODS
  The 100 patients (48 women, 52 men; median age, 49 yr) in the study were grouped as follows for treatment: SSA only (group A; n = 34); SSA followed by surgery (group B; n = 20); surgery only (group C; n = 30); and surgery followed by SSA (group D; n = 16).
  
  
  RESULTS
  At diagnosis, 28% had impaired glucose tolerance, and 22% had diabetes mellitus; fasting glucose levels (4.13-10.60 mmol/liter) were best predicted by age (t = 2.88; P = 0.0049) and disease duration (t = 1.99; P = 0.049). After 60 months, fasting glucose levels reduced (-4.9 +/- 19.7%) in group A only, whereas they did not change in the other groups. In the 68 nondiabetic patients at baseline, fasting glucose levels increased by 0.7 +/- 11.2%, 7.5 +/- 10.3%, 4.3 +/- 10.4%, and 4.3 +/- 14.8% (P = 0.28), from groups A to D, respectively. Percentage change of fasting glucose in all patients receiving SSA was 1.9 +/- 12.3%, and in those not receiving SSA it was 6.4 +/- 10.8% (P = 0.13). Overall, prevalence of new onset of diabetes during SSA treatment was nine of 55 (16.4%) vs. three of 23 after surgery (13.0%, P = 0.98). Deterioration of glucose tolerance was correlated with increased body mass index (r = 0.49, P < 0.0001) and not with use of SSA or surgery (r = 0.06; P = 0.53), control or not of GH (r = -0.10, P = 0.31) and IGF-I (r = -0.12; P = 0.22).
  
  
  CONCLUSIONS
  The results of this study demonstrate a similar deterioration of glucose tolerance after 60 months in patients receiving SSA or cured with surgery. Increase in body mass index was the major predictor of deterioration of glucose tolerance.
authors.affiliation: Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, University Federico II of Naples, via S. Pansini 5, 80131 Naples, Italy. colao@unina.it
authors.forename: Annamaria
authors.initials: A
authors.lastname: Colao
authors.forename: Renata S
authors.initials: RS
authors.lastname: Auriemma
authors.forename: Mariano
authors.initials: M
authors.lastname: Galdiero
authors.forename: Paolo
authors.initials: P
authors.lastname: Cappabianca
authors.forename: Luigi M
authors.initials: LM
authors.lastname: Cavallo
authors.forename: Felice
authors.initials: F
authors.lastname: Esposito
authors.forename: Ludovica F S
authors.initials: LF
authors.lastname: Grasso
authors.forename: Gaetano
authors.initials: G
authors.lastname: Lombardi
authors.forename: Rosario
authors.initials: R
authors.lastname: Pivonello
mesh_terms: D000172:Acromegaly / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery*; D000328:Adult; D000368:Aged; D000465:Algorithms; D001786:Blood Glucose / Q000378:metabolism*; D003131:Combined Modality Therapy; D003692:Delayed-Action Preparations; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000627:therapeutic use*; D015995:Prevalence; D011446:Prospective Studies; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D001786:Blood Glucose; D003692:Delayed-Action Preparations; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D015282:Octreotide